Title:
抗ＶＥＧＦ単一ドメイン抗体およびその応用
Document Type and Number:
Japanese Patent JP7336122
Kind Code:
B2
Abstract:
The present invention provides an anti-VEGF single-domain antibody and a use thereof. In particular, the present invention provides an anti-VEGF single-domain antibody and a VHH chain thereof. The present invention further provides a coding sequence for coding the single-domain antibody or the VHH chain thereof, a corresponding expression vector, a host cell capable of expressing the single-domain antibody, and a production method for the single-domain antibody of the present invention. The single-domain antibody of the present invention can specifically recognize human VEGFA and will not cause cross reactions with VEGFB, VEGFC and VEGFD, thus having a good specificity. The single-domain antibody of the present invention can further recognize VEGFAs of a human, a rat, a rabbit and a monkey, effectively blocks interactions between VEGFA and VEGFR2 and between VEGFA and VEGFR1, has an excellent inhibiting effect on angiogenesis, and has a good stability in a non-preparation condition.
Inventors:
Wanyakun
Zhu Min
▲ガイ▼ 軍偉
Shen Xiaoning
Zhu Min
▲ガイ▼ 軍偉
Shen Xiaoning
Application Number:
JP2022514739A
Publication Date:
August 31, 2023
Filing Date:
March 10, 2020
Export Citation:
Assignee:
SHANGHAI NOVAMAB BIOPHARMACEUTICALS CO.,LTD.
International Classes:
C12N15/13; A61K39/395; A61K47/68; C07K16/22; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63; C12P21/08; G01N33/53
Domestic Patent References:
| JP2013541939A | ||||
| JP2010518839A | ||||
| JP2013506411A | ||||
| JP2011505135A |
Foreign References:
| CN105820244A | ||||
| US20090269336 |
Attorney, Agent or Firm:
Patent Attorney Corporation Cosmos International Patent and Trademark Office